Loading…

Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement

Saved in:

Bibliographic Details
Published in:	Haematologica (Roma) 2015-03, Vol.100 (3), p.e99-e101
Main Authors:	Pigazzi, Martina, Manara, Elena, Buldini, Barbara, Beqiri, Valzerda, Bisio, Valeria, Tregnago, Claudia, Rondelli, Roberto, Masetti, Riccardo, Putti, Maria Caterina, Fagioli, Franca, Rizzari, Carmelo, Pession, Andrea, Locatelli, Franco, Basso, Giuseppe
Format:	Article
Language:	English
Subjects:	Antineoplastic Agents - therapeutic use Biomarkers, Tumor - genetics Child Child, Preschool Chromosomes, Human, Pair 21 Chromosomes, Human, Pair 8 Core Binding Factor Alpha 2 Subunit - genetics Cytarabine - therapeutic use Drug Monitoring Etoposide - therapeutic use Female Humans Idarubicin - therapeutic use Induction Chemotherapy - methods Infant Infant, Newborn Leukemia, Myeloid, Acute - diagnosis Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - mortality Male Mutation Neoplasm, Residual Online Only Proto-Oncogene Proteins - genetics RUNX1 Translocation Partner 1 Protein Survival Analysis Transcription Factors - genetics Translocation, Genetic
Citations:	Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!